Clinical effectiveness of Everolimus and Exemestane in advanced breast cancer patients from Asia and Africa: First efficacy and updated safety results from the phase IIIb EVEREXES study.

Im, Young-HyuckUslu, RuchanLee, Keun SeokNagarkar, Rajnish VasantSohn, JoohyukSevinc, AlperAltundag, KadriChang, Yuan-ChingAbdel-Razeq, HikmatIm, Seock-AhJeong, JoonPark, Ho YongArpornwirat, WichitBastick, Patricia A.Tuan Anh LeArikan, Ozlem OcakXue, Hong-LingCanatar, AycinValenti, RobertaKim, Sung-Bae2019-10-272019-10-2720150732-183X1527-7755https://doi.org/10.1200/jco.2015.33.15_suppl.e11579https://hdl.handle.net/11454/50504Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer -- MAY 29-JUN 02, 2015 -- Chicago, ILen10.1200/jco.2015.33.15_suppl.e11579info:eu-repo/semantics/closedAccessClinical effectiveness of Everolimus and Exemestane in advanced breast cancer patients from Asia and Africa: First efficacy and updated safety results from the phase IIIb EVEREXES study.Conference Object3315WOS:000358036902197Q1